on the use of CD22-specific CAR-T therapy in 21 patients with high-risk r/r LBCL and DLBCL after CD19-targeted CAR-T therapy failure, high rates of both overall objective response and complete remission were demonstrated, which were 86% and 61%, respectively (93). This evidence concerns the gene CD22 and diffuse large B-cell lymphoma.